QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy
Open Access
- 1 April 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in Pharmaceutical Biology
- Vol. 60 (1), 722-728
- https://doi.org/10.1080/13880209.2022.2056206
Abstract
QiShenYiQi pill (QSYQ) is a traditional Chinese medicine with a myocardial protective effect. To explore the effect of QSYQ on myocardial collagen metabolism in rats with autoimmune cardiomyopathy and explore the underlying mechanism from the aspect of apoptosis. We established an autoimmune cardiomyopathy model using Lewis rats. The rats were then randomly divided into six groups (n = 8): control, model, 3-methyladenine (15 mg/kg, intraperitoneal injection), QSYQ low-dose (135 mg/kg, gavage), QSYQ medium dose (270 mg/kg, gavage), and QSYQ high-dose (540 mg/kg, gavage) for four weeks. Van Gieson staining was applied for myocardial pathological characteristics, TUNEL fluorescence for myocardial cell apoptosis, enzyme-linked immunosorbent assay (ELISA) for serum PICP, PIIINP, and CTX-I levels, and western blot analysis for type I/III myocardial collagen, Bcl-2, Bax, and caspase-3 proteins. Results showed that QSYQ (135, 270, or 540 mg/kg) significantly reduced the expression of myocardial type I/III collagen, and concentrations of serum PICP, PIIINP, and CTX-I in rats. Moreover, QSYQ could alleviate myocardial fibrosis more effectively at a higher dose. QSYQ could also inhibit myocardial apoptosis via downregulating Bcl-2 expression, and upregulating Bax and caspase-3 expression levels. The QSYQ can improve myocardial collagen metabolism by inhibiting apoptosis, which provides a potential therapeutic approach for autoimmune cardiomyopathy.Keywords
Funding Information
- National Natural Science Foundation of China
- Young Talent Lifting Project of China Association of Chinese Medicine (CACM-, -QNRC2-B04)
This publication has 45 references indexed in Scilit:
- Ectopic trypsin in the myocardium promotes dilated cardiomyopathy after influenza A virus infectionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- In Vivo Delivery of Adenoviral Vector Containing Interleukin-17 Receptor A Reduces Cardiac Remodeling and Improves Myocardial Function in Viral Myocarditis Leading to Dilated CardiomyopathyPLOS ONE, 2013
- QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in RatsEvidence-Based Complementary and Alternative Medicine, 2013
- The Relationship Between Serum Markers of Collagen Turnover and Cardiovascular Outcome in the ElderlyCirculation: Heart Failure, 2011
- Cellular mechanisms of cardiomyopathyThe Journal of cell biology, 2011
- Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-KinaseOnline Journal of Public Health Informatics, 2010
- Immunomodulation and matrix metalloproteinases in viral myocarditisJournal of Molecular and Cellular Cardiology, 2010
- Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis — ongoing inflammation and an imbalance of the matrix degrading systemEuropean Journal of Pharmacology, 2010
- Long-term outcome of patients with biopsy-proved myocarditis: Comparison with idiopathic dilated cardiomyopathyJournal of Invasive Cardiology, 1995
- A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fractionClinical Immunology and Immunopathology, 1990